SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Uematsu M, Shioda A, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small-cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001; 51: 666-670.
  • 2
    Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007; 2( suppl 3): S94-S100.
  • 3
    Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009; 27: 3290-3296.
  • 4
    Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303: 1070-1076.
  • 5
    Haasbeek CJA, Lagerwaard FJ, Antonisse ME, Slotman BJ, Senan S. Stage I nonsmall cell lung cancer in patients aged >75 years. Outcomes after stereotactic radiotherapy. Cancer 2010; 116: 406-414.
  • 6
    Nagata Y, Hiraoka M, Mizowaki T, et al. Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys 2009; 75: 343-347.
  • 7
    Chang JY, Balter PA, Dong LD, et al. Stereotactic body radiation therapy in ventrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008; 72: 967-971.
  • 8
    Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early stage non-small-cell lung carcinoma: 4-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009; 75: 677-682.
  • 9
    Guckenberger M, Wulf J, Mueller G, et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 2009; 74: 47-54.
  • 10
    Nagata Y, Hiraoka M, Shibata T, et al. A phase II trial of stereotactic body radiation therapy for operable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group (JCOG0403) [abstract]. Int J Radiat Oncol Biol Phys 2010; 78( suppl): S27-S28.
  • 11
    Durand RE. Cell cycle kinetics in an in vitro tumor model. Cell Tissue Kinet 1976; 9: 403-412.
  • 12
    Shibamoto Y, Yukawa Y, Tsutsui K, Takahashi M, Abe M. Variation in the hypoxic fraction among mouse tumors of different types, sizes, and sites. Jpn J Cancer Res 1986; 77: 908-915.
  • 13
    Kallman RF, Rockwell S. Effects of radiation on animal tumor models. In: Adams GE, Kallman RF, eds. Cancer: A Comprehensive Treatise. Volume 6. New York: Plenum Press; 1977: 225-279.
  • 14
    Shibamoto Y, Kitakabu Y, Murata R, et al. Reoxygenation in the SCCVII tumor after KU-2285 sensitization plus single or fractionated irradiation. Int J Radiat Oncol Biol Phys 1994; 29: 583-586.
  • 15
    Murata R, Shibamoto Y, Sasai K, et al. Reoxygenation after single irradiation in rodent tumors of different types and sizes. Int J Radiat Oncol Biol Phys 1996; 34: 859-865.
  • 16
    Timmermann R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early stage lung cancer. J Clin Oncol 2006; 24: 4833-4839.
  • 17
    Baba F, Shibamoto Y, Tomita N, et al. Stereotactic body radiotherapy for stage I lung cancer and small lung metastasis: evaluation of an immobilization system for suppression of respiratory tumor movement and preliminary results [serial online]. Radiat Oncol 2009; 4: 15.
  • 18
    Iwata H, Shibamoto Y, Hashizume C, et al. Hypofractionated stereotactic body radiotherapy for primary and metastatic liver tumors using the Novalis image-guided system: preliminary results regarding efficacy and toxicity. Technol Cancer Res Treat 2010; 9: 619-627.
  • 19
    Koto M, Takai Y, Ogawa Y, et al. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol 2007; 85: 429-434.
  • 20
    Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery [published online ahead of print July 15, 2010]? Int J Radiat Oncol Biol Phys 2010.
  • 21
    Matsuo Y, Shibuya K, Nagata Y, et al. Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 79: 1104-1111.
  • 22
    Onimaru R, Fujino M, Yamazaki K, et al. Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. Int J Radiat Oncol Biol Phys 2009; 70: 374-381.
  • 23
    Takeda A, Sanuki N, Kunieda E, et al. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in 5 fractions to the periphery of the planning target volume calculated using a superposition algorithm. Int J Radiat Oncol Biol Phys 2009; 73: 442-448.
  • 24
    Brown JM, Diehn M, Loo BW. Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys 2010; 78: 323-327.
  • 25
    Willner J, Baier K, Caragiani E, Tschammler A, Flentje M. Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 52: 382-389.
  • 26
    Qiao X, Tullgren O, Lax I, Sirzen F, Lewensohn R. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer 2003; 41: 1-11.
  • 27
    Kestin LL, Grills IS, Guckenberger M, et al. Substantial dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance [abstract]. Int J Radiat Oncol Biol Phys 2010; 78( suppl): S14.
  • 28
    Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27: 131-146.
  • 29
    Petersen C, Eicheler W, Frommel A, et al. Proliferation and micromilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice. Int J Radiat Biol 2003; 79: 469-477.